



Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

Johannes Sam¹, Sara Colombetti¹, Tanja Fauti¹, Andreas Roller², Marlene Biehl¹, Linda Fahrni¹, Valeria Nicolini¹, Mario Perro¹, Tapan Nayak², Esther Bommer¹, Anne Schoenle¹, Maria Karagianni¹, Marine Le Clech¹, Nathalie Steinhoff¹, Christian Klein¹, Pablo Umaña^{1*} and Marina Bacac^{1*}

¹ Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland, ² Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland

Keywords: solid tumors, immunotherapy, T-cell bispecific antibody, carcinoembryonic antigen T-cell bispecific antibody, programmed death–ligand 1, combination, humanized mice

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Marina Bacac
marina.bacac@roche.com
Pablo Umaña
pablo.umana@roche.com

Specialty section:

This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Oncology

Received: 06 January 2021

Accepted: 12 January 2021

Published: 03 February 2021

Citation:

Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P and Bacac M (2021) Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. *Front. Oncol.* 11:650149. doi: 10.3389/fonc.2021.650149

A Corrigendum on

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

By Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P and Bacac M (2020). *Front. Oncol.* 10:575737. doi: 10.3389/fonc.2020.575737

In the published article, there was an error in affiliations 1 and 2. Instead of “Roche Pharmaceutical Research & Early Development”, it should be “Roche Pharma Research & Early Development”.

In the original article, there was an error in the **Conflict of Interest** section. Author ownership interests were omitted from the Conflict of Interest.

A correction has been made to the Conflict of Interest section:

The authors declare that this study received funding from F Hoffmann-La Roche Ltd. The funder had the following involvement with the study: study design, generation of the molecules tested in the study, data collection and analysis, decision to publish, and editorial support for the preparation of this manuscript. All authors are employees of F Hoffmann-La Roche Ltd. Authors JS, SC, TF, AR, MBi, LF, TN, AS, MLC, CK, PU, and MBa hold stock/stock options for F Hoffmann-La Roche Ltd and authors JS, SC, TF, VG-N, MP, TN, AS, CK, PU, and MBa hold patents related to the TCB technologies reported in the manuscript.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2021 Sam, Colombetti, Fauti, Roller, Biehl, Fahrni, Nicolini, Perro, Nayak, Bommer, Schoenle, Karagianni, Le Clech, Steinhoff, Klein, Umaña and Bacac. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.